Today, we?reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. Read the top highlights below and view the full announcement here: https://lnkd.in/dZNZ8EQ3 ? ?? Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; data from both studies anticipated by year-end 2025 ?? Oral small molecule amylin receptor agonist (ACCG-2671)?Phase 1?study?initiation anticipated by year-end 2025
Structure Therapeutics
生物技术研究
South San Francisco，California 7,507 位关注者
Developing accessible oral small molecule therapies for the treatment of chronic diseases including obesity.
关于我们
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
- 网站
-
https://structuretx.com/
Structure Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2017
- 领域
- Metabolic Diseases、Cardiovascular Diseases、Pulmonary、Diabetes、Computational Chemistry和Obesity
地点
Structure Therapeutics员工
动态
-
What better way to kick off the year than by bringing the full U.S. team together to celebrate our wins and set the stage for another year of growth. Congratulations to the recipients of our Foundation Awards. We believe strong foundations make bold visions possible. We recognized our U.S. teams for their dedication and contributions in helping to shape the future of Structure Therapeutics. We’re looking forward to more progress in 2025.
-
-
In honor of International Day of Women and Girls in Science, we are pleased to introduce our Women’s Leadership Network, Structure’s global internal organization dedicated to women’s empowerment, leadership and excellence. Hear from our founding members below on why we believe now is the perfect time to launch this initiative and our passion for uplifting the #WomenInScience at Structure and beyond. #WomenInSTEM #IDWGS
-
Last week, our team in Shanghai welcomed #LunarNewYear with a festive celebration including games, performers, traditional Chinese foods, good luck charms, and more. The Year of the Snake symbolizes deep thinking, intelligence, and a calm, strategic approach to challenges. These qualities inspire our work as we advance small molecule medicines for patients worldwide. Wishing our global team, partners, and community a year of success!
-
-
We have launched our new website! This transformation is more than a new look—it's a reaffirmation of our mission, our passion, and our relentless drive to make medicines more accessible to all. Patients are waiting for treatment options that are available, cost effective, and convenient. Explore our story and commitment to developing oral #smallmolecule therapeutics to treat #obesity and chronic diseases on our refreshed website here:?https://structuretx.com/
-
What an exciting?#JPM25! Our CEO Raymond Stevens shared our upcoming milestones and mission of greater accessibility for #obesity treatments with both?CNBC's Angelica Peebles and Bloomberg's Katie Greifeld.?#SmallMolecule approaches, like the ones?we are taking here at Structure,?hold promise for?greater?access?to long-term treatment options for people living with #obesity, in both affordability and availability. ? Learn more about our approach and our current Phase 2b clinical studies, ACCESS and ACCESS II for obesity in the clips below. ?? CNBC:?https://lnkd.in/ePane2aV ?? Bloomberg:?https://lnkd.in/eB-EAe4A
-
-
As we reflect on another remarkable year, we’re proud to celebrate the milestones that have shaped our journey at Structure. 2024 has been a testament to our team's dedication and our collective mission of advancing our clinical-stage pipeline in #obesity and in multiple disease areas including metabolic, cardiovascular, and others. With this momentum, we’re excited to move into 2025, to build on these achievements and continue making a meaningful impact. Thank you to everyone who has been along for our journey and helped us get to where we are today. From all of us at Structure, happy holidays, and we’ll see you in the new year!
-
We enjoyed coming together to make a difference this holiday season for our local partner CityTeam, an organization serving those experiencing homelessness, poverty, hunger and/or addiction. Our team prepared care bags filled with essential items and gifts. This has been a meaningful reminder of the impact we can make when we join forces for a shared cause, and we’re grateful for the opportunity to support CityTeam’s vital work.
-
-
We're excited to announce the selection of our lead oral small molecule amylin receptor agonist, ACCG-2671. #Amylin is a promising therapeutic target for #obesity and related diseases due to its effects on reducing food intake and slowing gastric emptying. ACCG-2671 was designed as an oral #smallmolecule dual amylin and calcitonin receptor agonist (#DACRA) and is expected to enter Phase 1 clinical development by year end 2025. Read the full announcement here:?https://lnkd.in/e7T9GCGv?
-